| Clinical overview of MDM2/X targeted therapies A Burgess, KM Chia, S Haupt, D Thomas, Y Haupt, E Lim Frontiers in Oncology 6, 7, 2016 | 398 | 2016 |
| The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer TE Hickey, LA Selth, KM Chia, G Laven-Law, HH Milioli, D Roden, ... Nature Medicine, 1-11, 2021 | 204 | 2021 |
| A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes EK Papachristou, K Kishore, AN Holding, K Harvey, TI Roumeliotis, ... Nature communications 9 (1), 2311, 2018 | 138 | 2018 |
| Targeting the androgen receptor in breast cancer KM Chia, M O’Brien, M Brown, E Lim Current oncology reports 17 (2), 1-6, 2015 | 122 | 2015 |
| A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer KM Chia, J Liu, GD Francis, A Naderi Neoplasia 13 (2), 154-166, 2011 | 105 | 2011 |
| Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle V Oakes, W Wang, B Harrington, WJ Lee, H Beamish, KM Chia, A Pinder, ... Cell Cycle 13 (20), 3302-3311, 2014 | 88 | 2014 |
| Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer A Naderi, KM Chia, J Liu Breast Cancer Research 13 (2), 1-16, 2011 | 69 | 2011 |
| MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer N Portman, HH Milioli, S Alexandrou, R Coulson, A Yong, KJ Fernandez, ... Breast Cancer Research 22 (1), 1-17, 2020 | 55 | 2020 |
| Non-canonical AR activity facilitates endocrine resistance in breast cancer KM Chia, H Milioli, N Portman, G Laven-Law, R Coulson, A Yong, ... Endocrine-Related Cancer 26 (2), 251-264, 2019 | 36 | 2019 |
| Defective decatenation checkpoint function is a common feature of melanoma K Brooks, KM Chia, L Spoerri, P Mukhopadhyay, M Wigan, M Stark, ... Journal of Investigative Dermatology 134 (1), 150-158, 2014 | 25 | 2014 |
| Inhibition of histone deacetylase 3 produces mitotic defects independent of alterations in histone H3 lysine 9 acetylation and methylation R Warrener, KM Chia, WD Warren, K Brooks, B Gabrielli Molecular pharmacology 78 (3), 384-393, 2010 | 23 | 2010 |
| A novel ATM‐dependent checkpoint defect distinct from loss of function mutation promotes genomic instability in melanoma L Spoerri, K Brooks, KM Chia, G Grossman, JJ Ellis, M Dahmer‐Heath, ... Pigment cell & melanoma research, 2016 | 16 | 2016 |
| Finally, how histone deacetylase inhibitors disrupt mitosis! B Gabrielli, KM Chia, R Warrener Cell Cycle 10 (16), 2658-2661, 2011 | 12 | 2011 |
| The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity KM Chia, H Beamish, K Jafferi, B Gabrielli Molecular pharmacology 78 (3), 436-443, 2010 | 12 | 2010 |
| Estrogen receptor positive breast cancer patient derived xenograft models in translational research KM Chia, A Freelander, S Kumar, A Parker, D Segara, N Portman, E Lim Current Opinion in Endocrine and Metabolic Research, 2020 | 3 | 2020 |
